Skip to main content
. Author manuscript; available in PMC: 2016 Feb 24.
Published in final edited form as: Radiother Oncol. 2013 Nov 11;109(3):388–393. doi: 10.1016/j.radonc.2013.10.021

Table 1.

The number (%) of patients with ≥ Grade 2 morbidity for each endpoint for the HUH and the BCCA cohort.

Endpoints
≥ Grade 2 RTOG GI Stool frequency Mucosal loss Tenesmus Sphincter control Rectal bleeding
HUH 14 (7%) 25 (11%) 24 (10%) 14 (6%) 10 (4%) 4 (2%)
BCCA - - - - - 12 (7.5%)

Grade 3
HUH - 1 (0.4%) 4 (2%) - 3 (1%) -
BCCA - - - - - 4 (3%)
Grade 4
HUH 1 (0.4%) - - - - -
BCCA - - - - - 1 (0.6%)